A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma

被引：0

作者：

Othman, Tamer ^{[1
,2
]}

Marquez-Arreguin, Gabriel ^{[1
]}

Esteghamat, Naseem ^{[1
]}

Tuscano, Joseph ^{[1
,3
]}

机构：

[1] Univ Calif Davis, Sch Med, Dept Internal Med, Div Malignant Hematol Cellular Therapy & Transplan, Sacramento, CA USA

[2] Univ Calif San Francisco, Sch Med, Dept Internal Med, Div Hematol & Oncol, San Francisco, CA USA

[3] Northern Calif Hlth Care Syst, Vet Adm, Martinez, CA USA

来源：

LEUKEMIA & LYMPHOMA | 2024年

关键词：

REFRACTORY FOLLICULAR LYMPHOMA; SINGLE-ARM; MULTICENTER; METHYLATION;

D O I：

10.1080/10428194.2024.2443552

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：4

共 50 条

[41] Phase I dose escalation study of fludarabine, bortezomib, and rituximab for relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Barr, P.
Fu, P.
Lazarus, H. M.
Bahlis, N. J.
Koc, O. N.
Horvath, N. J.
Cooper, B. W.
ANNALS OF ONCOLOGY, 2008, 19 : 209 - 209
[42] Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Kirschbaum, Mark
Frankel, Paul
Popplewell, Leslie
Zain, Jasmine
Delioukina, Maria
Pullarkat, Vinod
Matsuoka, Deron
Pulone, Bernadette
Rotter, Arnold J.
Espinoza-Delgado, Igor
Nademanee, Auayporn
Forman, Stephen J.
Gandara, David
Newman, Edward
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) : 1198 - 1203
[43] Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma
Moosmann, Peter
Heizmann, Marc
Kotrubczik, Nina
Wernli, Martin
Bargetzi, Mario
LEUKEMIA & LYMPHOMA, 2010, 51 (01) : 149 - 152
[44] Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma
Fowler, N. H.
McLaughlin, P.
Kwak, L.
Hagemeister, F.
Fanale, M.
Fayad, L.
Pro, B.
Samaniego, F.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[45] LENALIDOMIDE PLUS RITUXIMAB LEADS TO A HIGH RATE OF DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA
Dutia, M.
Deroock, I.
Reed-Pease, C.
Tuscano, J.
ANNALS OF ONCOLOGY, 2011, 22 : 186 - 186
[46] Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001
Witzig, T. E.
Wiernik, P. H.
Moore, T.
Reeder, C.
Cole, C.
Justice, G.
Kaplan, H.
Voralia, M.
Pietronigro, D.
Vose, J. M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[47] Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Ogura, Michinori
Uchida, Toshiki
Taniwaki, Masafumi
Ando, Kiyoshi
Watanabe, Takashi
Kasai, Masanobu
Matsumoto, Yosuke
Shimizu, Daisuke
Ogawa, Yoshiaki
Ohmachi, Ken
Yokoyama, Hiroki
Tobinai, Kensei
CANCER SCIENCE, 2010, 101 (09) : 2054 - 2058
[48] Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Ogura, Michinori
Tobinai, Kensei
Hatake, Kiyohiko
Uchida, Toshiki
Suzuki, Tatsuya
Kobayashi, Yukio
Mori, Masakazu
Terui, Yasuhito
Yokoyama, Masahiro
Hotta, Tomomitsu
CANCER SCIENCE, 2013, 104 (01) : 105 - 110
[49] A phase II trial of FavId™ [Id-KLH] for relapsed indolent non-Hodgkin's Lymphoma
Redfern, C
Guthrie, TH
Smith, MR
Adler, M
Holman, P
Leonard, JP
Levy, R
Densmore, J
Just, R
Rosenfelt, F
Wiernik, PH
Janakiraman, N
Winter, JN
Gold, D
Bender, JF
BLOOD, 2002, 100 (11) : 357A - 357A
[50] Lenalidomide oral monotherapy in relapsed/refractory small lymphocytic non-Hodgkin's lymphoma
Witzig, T. E.
Vose, J. M.
Justice, G.
Kaplan, H. G.
Reeder, C. B.
Pietronigro, D.
Takeshita, K.
Ervin-Haynes, A.
Zeldis, J. B.
Wiernik, P. H.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →